Skip to main content
. 2017 May 12;56(9):1498–1509. doi: 10.1093/rheumatology/kex174

Fig. 2.

Fig. 2

ASAS and ASDAS responses to week 204

CZP-randomized group, doses combined. (A) ASAS responses to week 204 in axSpA population. (B) ASAS40 to week 204 by subpopulations. (C) ASDAS-ID and ASDAS-MD to week 204 by subpopulations. (D) ASDAS score to week 204 by subpopulations. ASDAS: AS DAS; ASDAS-ID: ASDAS inactive disease; ASDAS-MD: ASDAS moderate activity; CZP: certolizumab pegol.